Biomolecular Companionship, Antioxidant, Anti-cancer and Anti- inflammatory properties of Cobalt (II) Schiff Base complex

Abstract

The spectrum properties of cobalt (III) complexes make them interesting anticancer drugs among other metallodrugs.  We want to test the anticancer effects of the ligand and the Co (III) complex by assuming that they are appropriately created from a new Schiff base ligand.  Curcumin and thiosemicarbazide hydrochloride were combined to produce a hexadentate ligand (L).  Macromolecular complexation with cobalt acetate salt in a 2:1 molar ratio yielded its deformed Co (III) complex.  H1 NMR spectroscopy, infrared (IR), thermogravimetric analysis (TGA), molar conductivity, and CHN elemental analysis were all used to provide light on the complex.  The complexation with the Co (III) ion caused the v (C=N), ν (C-N) phenolic, and ν (C-O) methoxy peaks to move to a higher wave number. At 672-693 and 442 - 456 cm-1, respectively, new peaks were seen that could be attributed to ν (Co-N) and ν (Co-S), suggesting that the ligand coordinated to the center of the Co3+ ion through its azomethine nitrogen, thio sulfur, and methoxy O groups.  The Co(L)2 compound exhibited paramagnetic properties with a µeff value of 7.93.  At temperatures of around 100 and 350 degrees Celsius, the thermal breakdown of the Co (III) complex occurred in two stages.  Compared to its Co (III) complex, the parent ligand has lesser activity in an anticancer study conducted on breast cancer cell lines (MCF-7).  When compared to ligand, the anticancer activity of the Co(L)2 complex is superior.  This study's Co (III) complex is an intriguing dual-acting drug with the potential to be turned into chemotherapeutics for many malignancies, including breast cancer, according to the current inquiry.